Studies the drug LTP001 in healthy adults and people with pulmonary arterial hypertension
Tests LTP001 in healthy adults, then in people with pulmonary arterial hypertension.
Plain-language title generated from the registry record
Registry title: A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Key facts
- Where
- Belgrade, Kamenitz, and Niš, SerbiaSee the 3 sites
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT06649110, who can take part
Where in Serbia
- BelgradeBelgrade, SerbiaTaking people
- KamenitzKamenitz, SerbiaTaking people
- NišNiš, SerbiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT06649110
- Record updated
- 21 July 2026
- Original description
A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)Read full original descriptionShow less
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of LTP001 in Healthy Adult Participants (Part A) and to Evaluate the Efficacy and Safety of LTP001 for the Treatment of Participants With Pulmonary Arterial Hypertension (Part B)
A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)
Part A Inclusion Criteria:; Healthy males and non-child-bearing potential females; Part A Exclusion Criteria:; Clinically significant ECG or cardiac abnormalities, any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the participant in the study Other protocol-defined inclusion/exclusion criteria may apply; For Japanese cohorts: participants per protocol should be first generation Japanese or up to third generation Japanese as defined in inclusion criteria 7 of the protocol; Part B Inclusion Criteria:; -Confirmed diagnosis of PAH, pre-randomization PVR ≥400 dyn.sec.cm-5, treatment with stable doses of standard-of-care PAH therapies, 6-minute walk distance ≥ 150 m and ≤450 m; Part B Exclusion Criteria:; Any surgical or medical condition which may place the participant at higher risk from his/her participation in the study Women of child-bearing potential unless they are using highly effective methods of contraception Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 24 hours after stopping study treatment; History of hypersensitivity to any of the study treatments or excipients; Other protocol-defined inclusion / exclusion criteria may apply.